Research progress in niraparib in the treatment of ovarian cancer / 肿瘤

ABSTRACT

Ovarian cancer is one of the three major gynecological tumors, and its incidence is increasing year by year. Although the current treatment of ovarian cancer has made great progress, the survival rate of patients with ovarian cancer is still low. It is a constant direction for clinicians and researchers to look for more effective treatment with fewer side effects. In recent years, the poly (ADP-ribose) polymerase (PARP) inhibitors are more widely used in the research of ovarian cancer. Niraparib, as a new PARP inhibitor, is the frst targeted drug for the treatment of recurrent ovarian epithelial cancer. Niraparib has a good therapeutic effect for breast cancer susceptibility gene (BRCA) wild type and mutant type of patients with ovarian cancer, especially when it combined with radiotherapy and chemotherapy. This article aims to summarize the application of niraparib in ovarian cancer.